₩ 3965
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Oncocross Co., Ltd. undertakes collaborative research initiatives to discover new drugs, partnering with a variety of pharmaceutical companies both within South Korea and abroad. The company offers a fresh paradigm for drug development by providing analytical insights derived from its advanced artificial intelligence drug discovery platform. Founded by Yi-Rang Kim on June 22, 2015, Oncocross operates from its headquarters located in Seoul, South Korea.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only